Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2010, Karyopharm has made significant strides in the industry, particularly with its flagship product, XPOVIO (selinexor), which targets the nuclear export protein XPO1 to enhance cancer treatment efficacy. With a strong presence in the oncology sector, Karyopharm is dedicated to addressing unmet medical needs through its unique approach to drug development. The company has achieved notable milestones, including regulatory approvals and partnerships that bolster its market position. Karyopharm's commitment to advancing therapeutic options underscores its role as a key player in the biopharmaceutical landscape, striving to improve patient outcomes globally.
DitchCarbon Score
How does Karyopharm Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Karyopharm Therapeutics Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Karyopharm Therapeutics Inc.'s reported carbon emissions
Karyopharm Therapeutics Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their carbon footprint in terms of Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. Without specific initiatives or targets outlined, it is unclear how Karyopharm is addressing climate change or its carbon emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Karyopharm Therapeutics Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
